


## AMENDMENTS TO THE CLAIMS

Kindly cancel claims 18 and 19 as provided in the following Claims Listing.


### Claims Listing:

1. (Previously Presented) A compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein

X includes the carbon atoms at positions 1 and 2 and is selected from




Y is H, oxo, or methyl;

R is selected from H, C<sub>1-7</sub> alkyl, C<sub>2-7</sub> alkenyl, C<sub>2-7</sub> alkynyl, C<sub>2-6</sub> heterocyclyl, C<sub>6-12</sub> aryl,

C<sub>7-14</sub> alkaryl, C<sub>3-10</sub> alkheterocyclyl, and C<sub>1-7</sub> heteroalkyl;

R<sub>1</sub> is H;

R<sub>4</sub> is H and R<sub>2</sub> and R<sub>3</sub> combine to form a fused six-membered ring in which position 4 is connected to position 5 by





Z is  $\text{-NHR}_5$ ; and

$\text{R}_5$  is H.

2. Canceled.

3. Canceled.


4. (Original) The compound of claim 1, wherein said compound is described by formulas II or III:



or a pharmaceutically acceptable salt thereof, wherein R is selected from H,  $\text{C}_{1-7}$  alkyl,  $\text{C}_{2-7}$  alkenyl,  $\text{C}_{2-7}$  alkynyl,  $\text{C}_{2-6}$  heterocyclyl,  $\text{C}_{6-12}$  aryl,  $\text{C}_{7-14}$  alkaryl,  $\text{C}_{3-10}$  alkheterocyclyl, and  $\text{C}_{1-7}$  heteroalkyl.

5-7. Canceled.

8. (Original) The compound of claim 1, wherein said compound is described by formula IX:




or a pharmaceutically acceptable salt thereof, wherein R is selected from H, C<sub>1-7</sub> alkyl, C<sub>2-7</sub> alkenyl, C<sub>2-7</sub> alkynyl, C<sub>2-6</sub> heterocyclyl, C<sub>6-12</sub> aryl, C<sub>7-14</sub> alkaryl, C<sub>3-10</sub> alkheterocyclyl, and C<sub>1-7</sub> heteroalkyl.

9. Canceled.

10. (Previously Presented) The compound of claim 4 or 8, wherein R is selected from CH<sub>3</sub>, CH<sub>2</sub>(cyclo-C<sub>4</sub>H<sub>7</sub>), CH<sub>2</sub>(cyclo-C<sub>3</sub>H<sub>5</sub>), CH(CH<sub>3</sub>)(cyclo-C<sub>3</sub>H<sub>5</sub>), CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>F, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>OCF<sub>3</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>CH=CH<sub>2</sub>, *trans*-CH<sub>2</sub>CH=CHI, CH<sub>2</sub>C≡CH, benzyl, phenethyl, 3,4-dichlorophenethyl, 3-furanylmethyl, 2-furanylmethyl, 3-tetrahydrofuranylmethyl, and 2-tetrahydrofuranylmethyl.

11. (Original) The compound of claim 10, wherein said compound has the structure



or a pharmaceutically acceptable salt thereof.

12-15. Canceled.

16. (Previously Presented) A pharmaceutical composition comprising an effective amount of a compound of any of claims 1, 4, 8, 10, or 11, or a suitable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

17. (Original) A method of treating pain in a patient in need thereof, said method comprising the step of administering to said patient a pharmaceutical composition of claim 16 in an amount sufficient to treat said pain.

18-22. Canceled.